### COMPANY UPDATE

# **Bangkok Chain Hospital PLC**



2019F 8,842 2,593 1,242

1,242 0.50 0.17 31.9 17.4 5.4 18.0 1.1

16.5

Thursday, November 30, 2017

## BUY

#### Stock Data

Last close (Nov 29) (Bt)	16.00
12-m target price (Bt)	21.00
Upside (Downside) to TP (%)	31.25
Mkt cap (Btbn)	39.90
Mkt cap (US\$mn)	1,225

Bloomberg code	BCH TB
Reuters code	BCH.BK
Risk rating	L
Mkt cap (%) SET	0.24
Sector % SET	4.30
Shares issued (mn)	2,494
Par value (Bt)	1.00
12-m high / low (Bt)	17.3 / 11.8
Avg. daily 6m (US\$mn)	4.46
Foreign limit / actual (%)	49 / 11
Free float (%)	50.0
Dividend policy (%)	≤ 40

#### **Price Performance**



Source: SET, SCBS Investment Research

#### Share performances

rawee

	1M	3M	12M
Absolute	(4.2)	8.8	13.5
Relative to SET	(3.4)	3.0	0.5
Source: SET, SCBS	Investmer	nt Resea	arch

## Striding to new highs in 2018

After a strong 2017, BCH's core earnings are continuing to march up to new highs in 2018, moving past the 2012 peak, underwritten by growing cash patient service after hospital upgrading, strong revenue from social security service and the first profit at World Medical Hospital. We maintain BUY with TP at Bt21/share.

**Hospital upgrading to serve higher medical complexity.** In 9M17, revenue from cash service excluding World Medical Hospital (54% of total revenue) grew 4% YoY off rising revenue per patient while patient volume was flat. We expect patient traffic to pick up after the completion of the renovation of six hospitals (~47% of total bed capacity), making it more convenient for patients to obtain care. At the same time, the upgrade in medical services in the renovated hospitals (e.g. adding OPD centers and expanding ICU) will allow it to provide more complex treatments, leading to a rise in revenue per patient.

**World Medical Hospital to profit in 2018.** World Medical Hospital, its high-end hospital accounting for 7% of revenue, has steadily improved and reported revenue of Bt159mn in 3Q17 (+37% YoY and +28% QoQ) and a cut in losses to Bt23mn (vs. losses of Bt34mn in 3Q16 and Bt36mn in 2Q17). Fueling this was the health checkup and antiaging treatment service for a patient group from China that began in 3Q17 and will continue in 2018. World Medical Hospital is now adding to its services, specifically an infertility center, and is negotiating to provide hospital management services for a hospital in Pakistan, which a conclusion expected this year. We forecast 2017 to be the last year of red ink for World Medical Hospital with a loss of Bt100mn, followed by growth to profit of Bt27mn (3% of BCH's core profit) in 2018.

**Positive on SC reimbursement through 1H18.** In 3017, revenue from social security service (SC, 37% of revenue), jumped 18% YoY on a 6% YoY rise in insured persons and a 12% YoY increase in average revenue per insured person, mainly from the hike in SC reimbursement effective in July 2017; this positive base effect will continue through 1H18. BCH updates that, in October, the Social Security Office adjusted payments for 26 chronic deceases and IPD service for less severe illnesses (RW<2): 1) changed budget allocation between 1H and 2H from 50:50 to 80:20 and 2) shortened verification process from 6 months to 4 months. This SC service (26 chronic deceases and IPD service for less severe (26 chronic deceases and IPD service for less severe (26 chronic deceases and IPD service for less severe (26 chronic deceases and IPD service for less severe (26 chronic deceases and IPD service for less severe (26 chronic deceases and IPD service for less severe (26 chronic deceases and IPD service for less severe illnesses (RW<2)) accounts for 19% of BCH's SC revenue (or 7% of total revenue). We note that the change in payment terms will not affect full-year comparison but may cause volatility off the base effect from quarter to quarter in 4Q17-3Q18 (Figure 1). BCH is talking with the auditor about the booking of revenue from this adjustment.

**2018 to be a stellar year. BUY with TP at Bt21/share.** We maintain our projection of core earnings growth of 16% YoY in 2017 and expect 2018 to be the best since 2012 before earnings were dragged by the opening of World Medical Hospital, with core earnings of Bt1.05bn (+21% YoY). We maintain BUY on BCH with TP at Bt21/share.

29.6

23.8

22.3

18.7

Raweenuch Piyakriengkai	Forecasts and valuation						
Fundamental Investment	Year to 31 Dec	Unit	2015	2016	2017F	2018F	
Analyst on Securities	Revenue	(Btmn)	5,766	6,511	7,109	8,065	
(66-2) 949-1002	EBITDA	(Btmn)	1,468	1,817	1,946	2,305	
enuch.piyakriengkai@scb.co.th	Core profit	(Btmn)	527	753	872	1,058	
	Reported profit	(Btmn)	527	753	872	1,058	
	Core EPS	(Bt)	0.21	0.30	0.35	0.42	
	DPS	(Bt)	0.07	0.17	0.12	0.15	
	P/E, core	(x)	75.2	52.7	45.5	37.5	
	EPS growth, core	(%)	1.0	42.8	15.7	21.4	
	P/BV, core	(x)	8.1	7.4	6.8	6.1	
nuch.piyakriengkai@scb.co.th	ROE	(%)	11.0	14.7	15.7	17.2	
	Dividend vield	(%)	0.4	11	0.8	0.9	

Source: SCBS Investment Research

**EV/EBITDA** 

Tel. (662) 949-1000 Fax: (662) 949-1030 www.scbs.com Tel information in this report has been obtained from sources believed to be reliable. However, its accuracy or completeness is not guaranteed. Any opinions expressed herein reflect our judgment at this date and are subject to change without notice. This report is for information only. It is not to be construed as an offer, or solicitation of an offer to sell or buy any securities. We accept no liability for any loss arising from the use of this document. We or our associates may have an interest in the companies mentioned therein.


(x)

### **Financial statement**

Profit and Loss Statement (B	tmn)				
FY December 31	2015	2016	2017F	2018F	2019F
Total revenue	5,766	6,511	7,109	8,065	8,842
Cost of goods sold	3,989	4,472	4,944	5,513	5,949
Gross profit	1,777	2,039	2,165	2,553	2,893
SG&A	855	835	845	921	1,003
Other income	86	98	98	109	118
Interest expense	163	162	175	140	147
Pre-tax profit	844	1,140	1,243	1,602	1,860
Corporate tax	174	208	199	320	372
Equity a/c profits	3	1	1	1	1
Minority interests	(145)	(180)	(174)	(225)	(248)
Core profit	527	753	872	1,058	1,242
Extra-ordinary items	-	-	-	· -	· -
Net Profit	527	753	872	1,058	1,242
EBITDA	1,468	1,817	1,946	2,305	2,593
Core EPS (Bt)	0.21	0.30	0.35	0.42	0.50
Net EPS (Bt)	0.21	0.30	0.35	0.42	0.50
DPS (Bt)	0.07	0.17	0.12	0.15	0.17
Balance Sheet (Btmn)					
FY December 31	2015	2016	2017F	2018F	2019F
Total current assets	2,137	1,937	2,376	2,340	2,655
Total fixed assets	7,859	8,039	8,265	8,546	8,883
Total assets	10,598	10,569	11,234	11,479	12,131
Total loans	4,462	4,078	4,200	3,700	3,500
Total current liabilities	3,042	2,621	4,323	4,880	4,724
Total long-term liabilities	2,510	2,498	1,002	3	4
Total liabilities	5,676	5,233	5,436	4,993	4,837
Paid-up capital	2,494	2,494	2,494	2,494	2,494
Total equity	4,922	5,337	5,797	6,486	7,294
BVPS (Bt)	1.97	2.14	2.32	2.60	2.92
Cash Flow Statement (Btmn)					
FY December 31	2015	2016	2017F	2018F	2019F
Core Profit	527	753	872	1,058	1,242
Depreciation and amortization	461	514	528	563	585
Operating cash flow	879	1,305	976	1,423	1,657
Investing cash flow	(553)	(684)	(712)	(807)	(885)
Financing cash flow	278	(854)	(289)	(869)	(634)
Net cash flow	367	(233)	(30)	(253)	139
Key Financial Ratios	0045		00475	00405	00405
	2015	2016	2017F	2018F	2019F
Gross margin(%)	30.8	31.3	30.4	31.7	32.7
Operating margin(%)	16.0	18.5	18.6	20.2	21.4
EBITDA margin(%)	25.5	27.9	27.4	28.6	29.3
EBIT margin(%)	17.2	19.7	19.7	21.3	22.4
Net profit margin(%)	9.1	11.6	12.3	13.1	14.0
ROE (%)	11.0	14.7	15.7	17.2	18.0
ROA (%)	5.1	7.1	8.0	9.3	10.5
Net D/E (x)	0.8	0.7	0.6	0.5	0.4
Interest coverage (x)	9.0	11.2	11.1	16.5	17.6
Debt service coverage (x)	1.7	0.9	1.1	0.7	0.7
Payout Ratio (%)	33.1	56.3	35.0	35.0	35.0

FY December 31	3Q16	4Q16	1Q17	2Q17	3Q17
Total revenue	1,747	1,693	1,622	1,676	2,004
Cost of goods sold	1,163	1,166	1,154	1,140	1,299
Gross profit	583	527	468	536	704
SG&A	219	222	209	271	226
Other income	23	26	26	27	16
Interest expense	28	39	39	28	34
Pre-tax profit	358	292	245	264	460
Corporate tax	65	49	40	51	95
Equity a/c profits	0	0	1	(0)	0
Minority interests	(50)	(45)	(41)	(40)	(63)
Core profit	243	198	165	172	303
Extra-ordinary items	-	-	-	-	-
Net Profit	243	198	165	172	303
EBITDA	520	463	415	424	628
Core EPS (Bt)	0.10	0.08	0.07	0.07	0.12
Net EPS (Bt)	0.10	0.08	0.07	0.07	0.12
Balance Sheet (Btmn)					
FY December 31	3016	4Q16	1017	2017	3Q17
Total current assets	1,983	1,937	2,134	1,958	2,089
Total fixed assets	7,978	8,039	8,122	8,543	8,604
Total assets	10,520	10,569	10,849	11,099	11,286
Total loans	4,285	4,078	4,178	4,521	4,505
Total current liabilities	2,816	2,621	3,689	3,026	2,208
Total long-term liabilities	2,498	2,498	1,498	2,495	3,345
Total liabilities	5,426	5,233	5,306	5,645	5,684
Paid-up capital	2,494	2,494	2,494	2,494	2,494
Total equity	5,094	5,337	5,543	5,454	5,602
BVPS (Bt)	2.04	2.14	2.22	2.19	2.25
Main Assumptions					
	2015	2016	2017F	2018F	2019F
<u>Revenue breakdown (%)</u>					
Cash service	63	63	60	61	62
Social security (SC)	36	37	39	38	37
Universal coverage (UC)	1	1	1	1	1

Profit and Loss Statement (Btmn)



#### 12-Month Cumulative directors trade

NA

#### 12 Month cumulative chg in foreign ownership versus cumulative chg in SET index





### Figure 1: Example of previous vs. new SC payment for 26 chronic deceases and IPD service (RW<2)

Period	1Q16	2Q16	3Q16	4Q16	1017	2017	3Q17	4Q17	1Q18	2Q18	3Q18	4Q18	1019	2019	3Q19	4Q19	
26 Chronic case and IPD (RW<2)	Service f	or 1H16	Service	for 2H16	Service	for 1H17	Service	for 2H17	Service for 1H18 Service			Service for 2H18		for 1H19	Service	for 2H19	
			Verification	.	Verifi	ation >	ion Verification			Verification				Verification >			
				1H16			2H16	1H17			2H17	1H18			2H18		
Previous payment				50% of SC budget			50% of SC budget	50% of SC budget			50% of SC budget	50% of SC budget			50% of SC budget		
New payment								1H17 80% of		2H17 20% of		1H18 80% of		2H18 20% of			
								SC budget Upside bias		SC budget Upside bias	Downside bias	SC budget		SC budget	l		

#### Source: BCH and SCBS Investment Research

#### Figure 2: Valuation summary (Closing price as of Nov 29, 2017)

	Rating	Price	Target	ETR	Р	/E (x)		EPS growth (%)			P/BV (x)			ROE (%)			Div. Yield (%)			EV/EBITDA (x)		
		(Bt/Sh)	(Bt/Sh)	(%)	16A	17F	18F	16A	17F	18F	16A	17F	18F	16A	17F	18F	16A	17F	18F	16A	17F	18F
BCH	Buy	16.00	21.0	32.2	53.0	45.8	37.7	43	16	21	7.5	6.9	6.2	15	16	17	1.1	0.8	0.9	23.9	22.4	18.8
BDMS	Buy	21.30	27.5	30.5	40.3	40.7	35.2	5	(1)	16	5.7	5.5	5.1	14	14	15	1.4	1.6	1.4	24.1	23.6	20.8
BH	Sell	206.00	210.0	3.4	41.7	39.8	35.3	6	5	13	10.1	9.2	8.1	26	24	24	1.2	1.3	1.4	25.9	24.3	21.7
CHG	Buy	2.32	3.5	53.2	45.2	42.5	32.4	5	7	31	7.9	7.4	6.7	18	18	22	1.6	1.9	2.4	28.5	24.9	19.7
Average					45.1	42.2	35.2	15	7	20	7.8	7.3	6.5	18	18	20	1.3	1.4	1.5	25.6	23.8	20.2

Source: SCBS Investment Research

#### Disclaimer

SCB SECURITIES COMPANY LIMITED ("SCBS") ACTS AS MARKET MAKER AND ISSUER OF DERIVATIVE WARRANTS on the ordinary shares AAV, ADVANC, AMATA, ANAN, AOT, AP, BA, BANPU, BBL, BCH, BCP, BCPG, BDMS, BEAUTY, BEC, BEM, BH, BIG, BJC, BLA, BLAND, BPP, BTS, CBG, CENTEL, CHG, CK, CKP, COM7, CPALL, CPF, CPN, DELTA, DTAC, EA, EGCO, EPG, ERW, GPT, GLOBAL, GLOW, GPSC, GUNKUL, HANA, HMPRO, ICHI, INTUCH, IRPC, ITD, IVL, KBANK, KCF, KKP, KTB, KTC, LH, LHBANK, LPN, MAOR, MEGA, MINT, MILS, PLANB, PSH, PTG, PTL, PTTP, PTTTP, PTTGC, CH, RATCH, ROBINS, S, SAMART, SAWAD, SCC, SCCC, SGP, SIRI, SPALI, SPCG, SPRC, STEC, STPI, SUPER, SVI, TASCO, TCAP, THAI, THANI, THCOM, TISCO, TKN, TMB, TOP, TPIPL, TRUE, TTA, TTCL, TU, UNIQ, VGI, WHA, WORK.

Before making an investment decision over a derivative warrant, an investor should carefully read the prospectus for the details of the said derivative warrants. Any opinion, news, research, analyse, price, statement, forecast, projection and/or other information contained in this document (the "Information") is provided as general purpose information only, and shall not be construed as a recommendation to any person of an offer to buy or sell, any securities. SCBS and/or its directors, officers, employees, and agents shall not be liable for any direct, indirect, incidental, special or consequential loss or damage, resulting from the use of, or reliance on, the Information, including without limitation, damages for loss of profits. The investor should use the Information association with other information and opinion, including his/her own judgment in making investment decision. The Information is obtained from sources believed to be reliable, and SCBS cannot guarantee the accuracy, completeness and/or correctness of the Information.

SCBS reserves the right to modify the Information from time to time at its sole discretion without giving any notice. This document is delivered to intended recipient(s) only and is not permitted to reproduce, retransmit, disseminate, sell, distribute, republish, circulate or commercially exploit the Information in any manner without the prior written consent of SCBS.

#### CG Rating 2017 Companies with CG Rating

ADVANC, AKP, ANAN, AOT, AP, BAFS, BANPU, BAY, BCP, BIGC, BTS, BWG, CFRESH, CHO, CK, CNT, CPF, CPN, CSL, DELTA, DEMCO, DRT, DTAC, DTC, EASTW, EGCO, GC, GCAP, GFPT, GOLD, GPSC, GRAMMY, GUNKUL, HANA, HMPRO, TOC, ICHI, INTUCH, IRPC, IVL, JSP, KBANK, KCE, KKP, KTB, KTC, LHBANK, LPN, MBK, MCOT, MINT, MONO, NCH, NKI, NYT, OTO, PHOL, PLANB, PPS, PRANDA, PRG, PSH, PSL, PTG, PTT\*, PTTE\*, PTTGC, PYLON, Q-CON, OH, OTC, RATCH, ROBINS, SAMART, SAMTEL, SAT, SC, SCB, SCC, SCCC, SE-ED, SIM, SIS, SITHAI, SNC, SPALI, SPRC, SSSC, STEC, SVI, SYNTEC, TCAP, THANA, THCOM, THREL, TISCO, TKT, TMB, TNDT, TOP, TRC, TRUE, TSC, TTCL, TU, TVD, UV, VGI, WACOAL, WAVE

#### 

25, AAV, ACAP, AGE, AH, AHC, AIRA, AIT, ALT, AMANAH, AMATA, AMATA, APCO, ARIP, ASIA, ASIMAR, ASK, ASP, AUCT, AYUD, BBL, BCPG, BDMS, BEC, BEM, BFIT, BJC, BJCHI, BLA, BOL, BROOK, BRR, BTW, CEN, CENTEL, CGH, CHARAN, CHEWA, CHG, CHOW, CI, CIG, CIMBT, CKP, CM, CNS, COL, COM7, CPI, CSC, CSP, CSS, DCC, EA, EASON, ECF, ECL, EE, EPG, ERW, FN, FNS, FORTH, FPI, FSMART, FVC, GBX, GEL, GLOBAL, GLOW, HARN, HOTPOT, HYDRO, ILINK, INET, IRC, ITI, ITD, JWD, K, KGI, KKC, KOOL, KSL, KTIS, L&E, LALIN, LANNA, LH, LHK, LIT, LOXLEY, LRH, LST, M, MACO, MAJOR, MAKRO, MALEE, MBKET, MC, MEGA, MFC, MOOR, MSC, MTI, MTS, NOBLE, NOK, NSI, NTV, NWR, OCC, OCC, OISHI, ORI, PATO, PB, PSGH, PDI, PF, OP, PJW, PLANEHT, PLAT, PM, PPP, RP, REPRE, PRINC, PT, RICHY, RWL, RS, NSMIN, SABINA, SALEE, SAMCO, SAWAD, SCG, SCI, SCN, SEAOLJ, SENA, SIPA, SINGER, SIRI, SMK, SMPC, SMT, SNP, SORKON, SPC, SPI, SPF, SR, SSF, ST, STA, STPI, SUC, SUSCO, SUTHA, SWC, SYNKC, SYNEX, TAE, TAKUNI, TASCO, TBSP, TCC, TEAM, TF, TFG, TGCI, THAI\*, THANI, THIP, THRE, TICON, TIRCO, TIW, TK, TKN, TKS, TMC, TMI, TMILL, TMT, TNITY, TNL, TOG, TPAC, TPACOP, TRT, TRU, TSE, TSR, TSTE, TSTH, TTA, TTW, TVI, TVO, TWP, TWPC, U, UAC, UMI, UP, UPGIC, UWC, VIH, VNT, WICE, WINNER, XO, YILASA ZMUCO YUASA, ZMICO

AEC, AEONTS, AF, AJ, AKR, ALLA, ALUCON, AMA, AMARIN, AMC, APURE, AQUA, ARROW, AS, ASEFA, ASIAN, ASN, ATP30, AU, BA, BCH, BEAUTY, BH, BIG, BIZ, BLAND, BPP, BR, BROCK, BTC, BTNC, CBG, CCET, CCP, CGD, CITY, CMR, COLOR, COMAN, CPL, CSR, CTW, CWT, DCON, DIGI, DNA, EFORL, EKH, EPCO, ESSO, ETE, FER, FOCUS, FSS, GENCO, GIFT, GJS, GLAND, GSTEL, GTB, GYT, HPT, HTC, HTECH, IFS, IHL, INSURE, IRCP, J, JMART, JMT, JUBILE, KASET, KBS, KCAR, KIAT, KWC, KYE, LDC, LEE, LH, MATCH, MATI, M-CHAI, MDX, METCO, MGT, MILL, MJD, MK, MODERN, MPG, NC, NCL, NDR, NEP, NETBAY, NPK, NPP, NUSA, OCEAN, PDG, PF, PICO, PIMO, PK, PL, PLE, PMTA, PRECHA, PRIN, PSTC, OLT, RCI, RIL, ROJNA, RES, SI, SANE, SSE, SSP, SSE

me survey result is so the bar photome opporting in the composite overname report of that is the contract companies. As a result, the survey result may be changed after that bare. Sob Securities of the accuracy of such survey result. BIGC was voluntarily delisted from the Stock Exchange of Thailand effectively on September 28, 2017 \* บริษัทหรือกรรมการหรือผู้บริหารของบริษัทที่มีข่าวด้านการกำกับดูแลกิจการ เช่น การกระทำผิดเกี่ยวกับหลักทรัพย์ การทุจริด คอร์รัปขั้น เป็นดัน ซึ่งการใช้ข้อมูล CGR ควรตระหนักถึงข่าวดังกล่าวประกอบด้วย

#### Anti-corruption Progress Indicato

Anti-corruption Progress Indicator
Certified (16%unrs%usa)
DAVANC, AKP, AMANAH, AP, ASP, AYUD, BAFS, BANPU, BAY, BBL, BCP, BKI, BLA, BROOK, BTS, BWG, CENTEL, CFRESH, CIMBT, CM, CNS, CPI, CPN, CSL, DCC, DEMCO, DIMET, DRT, DTAC, DTC, EASTW, ECL, EGCO, FE, FNS, FSS,
GBX, GCAP, GLOW, HANA, HMPRO, HTC, ICC, IFEC, INTUCH, IRPC, IVL, K, KBANK, KCE, KGI, KKP, KSL, KTB, KTC, LANNA, LHBANK, LHK, LPN, MBK, MBKET, MCOT, MFC, MINT, MONO, MOONG, MSC, MTI, NKI, NSI, OCC, OCEAN, PB,
PDI, PE, PG, PHOL, PLAT, PM, PPP, PPS, PRANDA, PREB, PRG, PSH, PSL, PT, PTG, PTT, PTTEP, PTTCC, Q-CON, OH, QLT, RATCH, RML, ROBINS, S & J, SABINA, SAT, SCB, SCC, SCG, SGP, SINGER, SIS, SITHAI, SMIT, SMPC, SNC, SNP,
SORKON, SPC, SPI, SSF, SSI, SSSC, SVI, SYNTEC, TAE, TCAP, TCMC, TFG, TGCI, THANI, THCOM, THRE, THREL, TIPCO, TISCO, TKT, TMB, TMD, TNITY, TNL, TOG, TOP, TPCORP, TRU, TSC, TSTH, TTCL, TVI, UOBKH, WACOAL
Declared (Jssnnifeaursun)
A, AI, E, AIRA, AJ, ALUCON, AMATAV, AOT, APCO, AQUA, ARROW, ASIA, ASK, AU, BCH, BJC, BJCHI, BLAND, BR, BROCK, BRR, CEN, CGH, CHEWA, CHG, CHOTI, CHOW, CIG, COL, COMT, CPALL, CPF, CPR, CSC, EKH, EPCO, FC, FEP,
FPI, FSMART, GEL, GFPT, GCC, GIFT, GJS, GLOBAL, GOLD, GPSC, GREEN, GSTEL, GUUNKUL, HARN, IFS, ILINK, INFT, IRC, J, JMART, JMT, JMIEL, JUTHA, KASET, KBS, KCAR, KTECH, KWC, KYE, LEE, LIT, LVT, MARO, MATCH,
MATI, MBAX, MC, MEEC, MIDA, MILL, ML, MTLS, NBC, NCL, NPP, NINE, NING, NNCL, NTV, NUSA, NWR, GGC, PACE, PAF, PAP, PATO, PCSGH, PIMO, PK, PL, PLANB, POST, PRINC, PRO, PSTC, PYLON, QTC, ROH, ROUNA, RAWI, SANKO,
SAUCE, SC, SCC, SCN, SEAOIL, SE-EAD, SENA, SIRI, SMART, SPACK, SPPT, SPR, CSR, SRI, SUGA, SST, ASUPER, SUSCO, SWC, SYMC, TAKUNI, TBSP, TFI, THE, TICON, TIP, KN, TLUXE, TMILL, TMT, TNP, TPA, TRUE, TSE, TTI, TU,
TVD, TVD, TVD, TVD, UL, PL, UNEKA, UWC, VGI, VIBHA, VIH, WIT, WAYE, WHA TVD, TVO, TVT, TWPC, U, UPA, UREKA, UWC, VGI, VIBHA, VIH, VNT, WAVE, WHA, WICE, WIIK

UBIS, UEC, UKEM, UMI, UMS, UNIQ, UP, UPF, UPOIC, UT, UTP, UV, UVAN, VARO, VI, VNG, VPO, VTE, WG, WHAUP, WIN, WINNER, WORK, WORLD, WP, WPH, WR, XO, YCI, YNP, YUASA, ZIGA, ZMICC

Explanations Companies participating in Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of July 31, 2017) are categorised into: companies that have declared their intention to join CAC, and companies certified by CAC.

